New study: urinary NGAL testing improves the ability to distinguish between intrinsic and non-intrinsic AKI, addressing a key limitation of serum creatinine. Read more: pubmed.ncbi.nlm.nih.gov/40802457/

Still relying on serum creatinine to identify patients with AKI? Visit us today and tomorrow in the exhibit hall at the Canadian Critical Care Forum (Table 16) to learn how NGAL testing can help you manage AKI earlier. #ICU #CriticalCare #CCCF2025

As we reflect on another year of success, we extend our heartfelt gratitude to our incredible employees, loyal customers, dedicated investors, collaborators, researchers, and clinicians — and to the impact our NGAL products have in advancing patient care and kidney health. Thank you!

Attending the Canadian Critical Care Forum? Come visit us at booth #16 to discuss how the NGAL biomarker can help improve outcomes for critically-ill patients. BioPorto attendees: Matt Grimmig and Sheila Schwabe

Attending American Society of Nephrology's annual meeting this November? Let's connect - visit us at booth 1342.

Discover how the NGAL biomarker is transforming pediatric care – one child at a time, across continents. Join us at #ESPN2025 booth 26 for an exclusive "Meet the Experts" session with NGAL experts. Oct 17 10:30-11:00 ESPN 2025, Stand 26

"Attending #PCICS2025? Visit us at table 33 to learn about ProNephro AKI (NGAL) – the first test for AKI risk assessment in ICU patients 3 months to 22 years. #NGAL4kids #PedsICU

The BioPorto team is excited to be part of the 5th International Symposium on AKI in Children hosted by Cincinnati Children's Hospital. Visit us in the exhibit hall, connect with us in a session or schedule some time to meet BioPorto's new CEO, Carsten Buhl.

Today we are excited to celebrate a significant milestone in bringing NGAL testing to US clinicians and patients. Our first commercial shipment of ProNephro AKI (NGAL) for cobas® c 501 is on its way to Roche in Germany, where it will make the next leg of its journey to Indianapolis. bit.ly/4lNoh9q

How do you see NGAL affecting your practice in terms of revealing AKI and triggering application of CCRT and starting different interventions?” asks Prof. Claudio Ronco in this episode of Cappuccino with Claudio. www.youtube.com/watch?v=bu-o...

Attending #IPTA2025 in Berlin? Don’t miss this opportunity to learn more about using the NGAL biomarker to manage acute kidney injury in transplant patients. 📅 Sept 19 ⏰ 12:20-13:20 Clinical Experts: Drs. Jun Oh and Kyle Merrill Moderator: Katherine Twombley @iptapedstx.bsky.social

Just announced! BioPorto is sponsoring a U.S. News & World Report webinar: “New Frontiers in Kidney Care” – Sept 11 at 1PM ET Join leading kidney experts to explore how innovation is improving outcomes for both acute and chronic kidney conditions. Register free here: lnkd.in/d64idJ_w

Attending #ESPNIC2025? Join us for lunch and learn about NGAL for managing fluids in your critically ill AKI patients, or visit us at stand 23 in the exhibit hall. #NGAL4kids @espnic.bsky.social Lunch Symposium 🗓️ June 26 ⏰ 13:00, Crystal Room Speakers: Zaccari Ricci, Raj Basu, Giovanni Ceschia

‪@jzngal.bsky.social and Alexandra Bahr are excited for the #43vicenzacourse next week to learn about the latest advancements in earlier diagnosis of #AKI and #CRRT initiation & liberation using kidney biomarkers. Connect with them during a session or schedule a time to meet. bit.ly/3Y9QXxF

Don’t miss Prof. Shacham’s poster presentation at #43VicenzaCourse where he will share how NGAL can aid in early risk stratification for STEMI patients at risk of AKD. This is a great opportunity to learn how NGAL can help improve patient outcomes. #KidneyHealthForAll #AKD

We look forward to the upcoming #ERA25 oral presentations on June 5th in Vienna. Dr. Strader will explore real-world experiences in applying urinary NGAL testing in clinical practice, and Dr. Shacham will share the value of NGAL in earlier risk stratification for predicting AKD in STEMI patients.

Today, we celebrate #ICU teams worldwide for their collaboration to drive technological and therapeutic advances while delivering compassionate, quality, patient-centered, and personalized care. #CritCareMonth #BlueICU @sccmcriticalcare.bsky.social @critcaremed.bsky.social @espnic.bsky.social

Today, we celebrate World PICU Awareness Day by recognizing PICU teams worldwide for their relentless efforts in driving impactful and innovative solutions for continued improvement in pediatric critical care. #CritCareMonth #WPAW25 #PedsICU @wfpiccs.bsky.social @espnic.bsky.social

We are excited to see #AKI on the program at #EuroMedLab 2025. Don’t miss sessions by Joe El-Khoury and Marlies Ostermann. While you’re there, connect with @jzngal.bsky.social to learn more about BioPorto’s NGAL tests for earlier AKI identification and management, & our adult trial. #CritCare #ICU

Join the ISCCN community for research, education and professional development dedicated to critical care nephrology. #NephCritCare 📸 Lui Forni, MD – founder & board member Mitra Nadim, MD – early joiner Join today: isccn.org

AKI in pediatric solid organ transplant patients is common, affecting 37-57%, depending on the type of transplanted organ. Ask us how BioPorto’s NGAL tests can help you assess AKI risk in these vulnerable patients. #KidsTransplantWeek #NGAL4kids

This #LabWeek, we celebrate all labs working hard to save patients’ lives, from our lab teams in Denmark creating our NGAL products to our customer labs using NGAL to identify and manage acute kidney injury. #ASCPLabWeek25 #LabsSaveLives #GlobalMedLabWeek

As #NationalKidneyMonth ends, we stress early AKI detection to protect long-term kidney health. In >29,000 critical illness survivors, the AKI rate was 59.2%. Patients with non-recovery from AKI at hospital discharge had the highest 15-year mortality. PMID: 36848723 #NGAL #AKI